Experts involved in developing a vaccine against the emerging coronavirus in the United States fear that the Donald Trump administration will seek approval to use the drug before the November presidential election.

The New York Times, quoting informed sources, said that some employees of the departments of the American companies involved in making the vaccine are "constantly under pressure from the White House, which hopes to obtain good news." They stress that they are "afraid of political interference" in this work in the coming months.

The newspaper added: "Experts inside and outside the government fear that the White House will press the US Food and Drug Quality Administration to overlook any lack of necessary data, and urgently and urgently agree to the use of the vaccine even for specific groups of people, before the November 3 elections. ".

The article included comments from Paul Offit, a Pennsylvania State University specialist on the FDA's emerging vaccine advisory board. This specialist believes that the Washington administration may speed up the approval of the vaccine. According to the expert, some specialists are "really worried about that."

Source: Tass

By:Nadeemy Haded

Rate this item
(0 votes)

About us

 Castle Journal is an international newspaper with daily electronic edition, received the international license by the United Kingdom number 10675, and accredited by the Egyptian Embassy in London, owned by Abeer Almadawy

Castle Journal expresses on the free and human voice specialized in the diplomatic, cultural and scientific media, it is eager to create a close relationship with the readers, who is our priority and considers them a true partner.

Castle Journal holds all the permits for practicing its duties of journalism in all countries of the world and the international organizations